Tristel earnings increased in the year ended June 30, 2026, with adjusted pre-tax profit rising 15% to £11.7 million on revenue growth of 10% to £51.1 million. The hospital infection-prevention products manufacturer announced the audited results on October 19, 2026, alongside a proposed final dividend that would lift its full-year payout by 5%.
Key Takeaways
- Reported pre-tax profit rose 30% to £11.0 million, outpacing adjusted profit growth.
- Medical-device product sales led growth, while overseas markets supplied 64% of revenue.
- The proposed 9.23p final dividend would bring the annual payout to 14.91p per share.
Table of Contents
- Tristel earnings grow faster than revenue
- Medical devices and international markets support growth
- New leadership and a paid digital offering enter FY2027
- Board proposes a higher final dividend
- Conclusion
Tristel earnings grow faster than revenue
Tristel’s audited FY2026 results announcement showed trading in line with market expectations and internal performance targets. Revenue increased from £46.5 million a year earlier, while adjusted pre-tax profit rose from £10.1 million.
Statutory pre-tax profit increased from £8.4 million to £11.0 million. The adjusted measure excludes Research and Development Expenditure Credit, share-based payments and exceptional items, making it distinct from reported profit.
The company maintained an adjusted EBITDA margin above its 25% target while investing in commercial capabilities, clinical evidence, product development, digital infrastructure and the United States. Cash and short-term investments reached £16.0 million, compared with £12.8 million a year earlier. Tristel had no debt apart from lease liabilities.
| Item | Details |
|---|---|
| Gross margin | 82% in FY2026, compared with 81% in FY2025 |
| Adjusted earnings per share | 18.19p, up 6% from 17.15p |
| Basic earnings per share | 16.68p, compared with 13.92p |
| Operating cash flow | £11.1 million, compared with £10.3 million |
Medical devices and international markets support growth
Sales in the medical-device business increased 11% to £45.0 million. Tristel Surfaces, its environmental surface-disinfection range, contributed £4.7 million, compared with £3.7 million in FY2025. Overseas markets accounted for 64% of group revenue, up from 63%.
Tristel said growth across the UK and several key European markets was accompanied by a materially larger US contribution. Following FDA clearance of ULT for ultrasound probes and OPH for ophthalmic devices, the North American focus increasingly shifted from regulatory entry to commercial adoption.
The company also completed its transition to in-house wipe manufacturing, with efficiencies beginning to emerge during the year. Its new VISICLEAN product adds visible confirmation of the cleaning step to its ultrasound decontamination offering.
New leadership and a paid digital offering enter FY2027
Chris Lee became chief executive on August 1, 2026, after the financial year ended. He identified growing US adoption and continued investment in commercial and digital capabilities among the company’s priorities.
After year-end, Tristel launched 3T Pro, the first paid premium tier of its digital compliance platform. The launch creates an opportunity for recurring digital revenue alongside the core consumables business; the announcement did not quantify its revenue contribution.
Board proposes a higher final dividend
The board recommended a final dividend of 9.23p per share, up from 8.52p. Together with the 5.68p interim dividend, that would take the full-year payout to 14.91p, compared with 14.20p for FY2025.
The announced timetable sets November 26, 2026, as the ex-dividend date and November 27 as the record date, with payment scheduled for December 17.
Conclusion
Tristel enters FY2027 with higher profits, more cash and an expanded product offering. The next dated shareholder milestone is the November 26 ex-dividend date for the proposed final payout, followed by the scheduled December 17 payment.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
